Gufic BioSciences Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 3 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹4.0K Cr
Indore facility peak revenue expected around Rs. Indore facility expected to start EBITDA breakeven in FY '26 and become bottom-line accretive by FY '27. - Peak revenue from Indore anticipated around Rs.
From Gufic BioSciences Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹432
Market Cap
₹4.0K Cr
P/E Ratio
62.6
How does Gufic BioSciences Ltd rank in Pharmaceuticals & Biotechnology?
Compare Gufic BioSciences Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Gufic BioSciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹231 Cr, net profit ₹12 Cr.
Full financials →📊 Revenue & Sales Performance
- →Indore facility peak revenue expected around Rs. 800 crore by FY 2028, reaching 70%-75% capacity utilization.
- →Revenue from Indore in FY 2026 projected between Rs. 100 to 150 crore, reaching EBITDA breakeven in FY 2026 and full profitability by FY 2027.
- →International business expected to grow from 16%-18% to about 25% of total revenue in next 2-3 years, potentially doubling exports in 3-5 years.
- →Contrast-media basket projected to contribute 5%-6% to the critical care segment within 2-3 years, expanding with new Gado-based product launches.
- →Critical care segment contributes over 50% of domestic revenue; infertility around 25%.
- →Botulinum toxin market penetration to reach 20%-26% in aesthetics and neurology within 3 years, aiming for Rs. 100 crore revenue.
- →Expected overall revenue growth rate of 15%-20% year-over-year in the next couple of years.
📈 Profitability & Margins
- →Indore facility expected to start EBITDA breakeven in FY '26 and become bottom-line accretive by FY '27.
- →Peak revenue from Indore anticipated around Rs. 750-800 crores by FY '28 with 70%-75% capacity utilization.
- →Overall company revenue growth targeted at 15%-20% year-over-year for next 2 years.
- →International business expected to grow 1.5x to 2x in next 3 to 5 years, contributing ~25% of revenue.
- →EBITDA margin pressure due to Indore fixed costs, interest, and depreciation expected to ease by FY '26.
- →PAT margin was 8.53% for current financial year; improvement expected as Indore facility scales up.
- →Expanded product basket (e.g., contrast media, Botulinum toxin, IVIG) to support revenue and profitability growth.
- →Overall growth driven by domestic and international market expansions, product launches, and regulatory approvals.
🏗️ Capital Expenditure Plans
- →Indore facility is a key strategic capital investment, recently capitalized in Q3 FY '25.
- →Loan of Rs. 160 crore taken for Indore plant (Rs. 100 crore from Saraswat Bank and Rs. 60 crore from HDFC Bank).
- →Indore underwent extended media-fill and aseptic process validations to ensure export market compliance.
- →Indore plant poised to ramp up to ~30% capacity in FY '26 to achieve EBITDA breakeven; expected to be bottom-line accretive by FY '27.
- →Tech transfers initiated for 33 SKUs at Indore, with 15-18 completed, highlighting ongoing product development and capacity expansion.
- →Additional product launches planned, e.g., Gado-based contrast media and new biosimilars in fertility and neurocare divisions.
- →Company investing in product trials and clinical studies to support growth in critical care, fertility, and aesthetic segments.
- →Distribution expansion through international marketing (e.g., LATAM countries) indicates strategic market investment.
💰 Fundraising & Capital Structure
📋 Order Book & Pipeline
- →The company has booked 16 major customer audits for its CMO business.
- →Five global regulatory inspections have been notified, with mock inspections underway.
- →Technology transfers for 33 SKUs from Navsari and 18 site transfers from other CMO partners are in progress.
- →Development of 15 new products at the Indore R&D center is in advanced stages.
- →The company has headroom to accept additional domestic orders currently.
- →However, excessive production is being avoided during the critical regulatory audit phase to maintain asset integrity.
Key Metrics
Continue your research
What Gufic BioSciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Biocon (Q4 FY25)
FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page…
- Natural Capsules (Q4 FY25)
196 crore, implying about Rs. Key concall takeaways from Natural Capsules Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Laurus Labs (Q4 FY25)
Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt. Key concall takeaways from Laurus Labs…
- Wockhardt Ltd (Q4 FY25)
EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%. Key concall takeaways from Wockhardt…
Frequently Asked Questions
What were Gufic BioSciences Ltd Q4 FY25 results?
Indore facility peak revenue expected around Rs. Indore facility expected to start EBITDA breakeven in FY '26 and become bottom-line accretive by FY '27. - Peak revenue from Indore anticipated around Rs.
What is Gufic BioSciences Ltd share price analysis?
Gufic BioSciences Ltd currently shows a neutral. The stock trades at a P/E of 62.6 with a market cap of ₹3,955 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gufic BioSciences Ltd planning capital expenditure?
Indore facility is a key strategic capital investment, recently capitalized in Q3 FY '25. - Loan of Rs.
Keep Gufic BioSciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.